Azacytidine

DRUG17 trials

Sponsors

Swiss Cancer Institute, Università degli Studi di Brescia, Weill Medical College of Cornell University, M.D. Anderson Cancer Center, Therapeutic Advances in Childhood Leukemia Consortium

Conditions

Acute Myelogenous LeukemiaAcute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaAcute Myeloid LeukemiaCarcinoma, Non-Small Cell LungDLBCL - Diffuse Large B Cell LymphomaDiffuse Large B Cell LymphomaEpithelial Malignancies (Excluding Lung and Renal Cell Carcinomas)Germ Cell Tumors

Phase 1

Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma

CompletedNCT01004991

Weill Medical College of Cornell UniversityDiffuse Large B Cell Lymphoma

Start: 2010-01-31End: 2016-02-29Updated: 2017-04-10

Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)

CompletedNCT01120834

Weill Medical College of Cornell UniversityLymphoma

Start: 2010-09-30End: 2016-10-20Updated: 2017-04-10

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

CompletedNCT01861002

Therapeutic Advances in Childhood Leukemia ConsortiumLymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood

Start: 2013-05-22End: 2014-07-28Updated: 2021-06-09

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

CompletedNCT02400281

Arog Pharmaceuticals, Inc.Acute Myeloid Leukemia

Start: 2015-09-30End: 2020-07-15Updated: 2024-07-03

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

WithdrawnNCT04648826

National Cancer Institute (NCI)Epithelial Malignancies (Excluding Lung and Renal Cell Carcinomas), Germ Cell Tumors, Melanomas +2

Start: 2021-12-14End: 2021-12-14Updated: 2021-12-17

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Not yet recruitingNCT06694454

National Cancer Institute (NCI)Carcinoma, Non-Small Cell Lung, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer (NSCLC) +2

Start: 2026-04-08End: 2034-12-31Target: 60Updated: 2026-04-03

Phase 2

Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy

CompletedNCT00739388

Swiss Cancer InstituteLeukemia

Start: 2008-07-31End: 2012-11-30Updated: 2013-04-10

5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs)

CompletedNCT00897130

Università degli Studi di BresciaMyelodysplastic Syndrome

Start: 2008-08-31End: 2014-12-31Updated: 2014-12-03

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

TerminatedNCT01542684

M.D. Anderson Cancer CenterLeukemia

Start: 2012-03-31End: 2013-04-30Updated: 2014-04-30

Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.

CompletedNCT02017457

Carlos Graux, MD, PhDAcute Myelogenous Leukemia, Myelodysplastic Syndrome

Start: 2013-12-31End: 2019-11-30Updated: 2019-12-10

Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

CompletedNCT02196857

M.D. Anderson Cancer CenterLeukemia

Start: 2015-02-06End: 2018-11-27Updated: 2020-01-14

Azacytidine Plus FLAG for Relapsed or Refractory AML

King Fahad Medical CityAcute Myeloid Leukemia

Start: 2014-12-31End: 2018-10-31Target: 37Updated: 2015-01-06

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

RecruitingNCT04747236

University of VirginiaPTCL

Start: 2021-02-19End: 2030-06-02Target: 50Updated: 2026-01-21

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

RecruitingNCT05355051

M.D. Anderson Cancer CenterHodgkin's Lymphoma

Start: 2022-10-05End: 2026-12-31Target: 24Updated: 2025-10-24

AZA Combined with R-GemOx for Elderly DLBCL Patients

Not yet recruitingNCT06778902

Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityDLBCL - Diffuse Large B Cell Lymphoma

Start: 2025-02-01End: 2028-01-01Target: 80Updated: 2025-01-16

Phase 4

Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy

Shenzhen Second People's HospitalAcute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia

Start: 2019-09-01End: 2023-06-01Target: 114Updated: 2022-03-15

Unknown Phase

Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine

Assistance Publique Hopitaux De MarseilleMyelodysplastic Syndromes, Myeloid Leukemia

Start: 2015-08-31End: 2019-03-31Target: 35Updated: 2015-07-03

Related Papers

Population Pharmacokinetics and Exposure–Response Analysis of Serplulimab in Small Cell Lung Cancer Patients

Clinical and Translational Science2025-09-01

Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

Cancers2024-01-248 citations

A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma - a Bridge to Transplant and an Effective Salvage for the Unfit

Blood2022-11-153 citations

Sorafenib Combined with 5‐azacytidine in Older Patients with Untreated <i>FLT3</i>‐ITD Mutated Acute Myeloid Leukemia

American Journal of Hematology2018-07-20115 citations

Sorafenib plus 5-azacytidine (AZA) in older untreated <i>FLT3</i>-ITD mutated AML.

Journal of Clinical Oncology2017-05-202 citations

A Phase 1 Study of Azacitidine (AZA) in Combination with Fludarabine and Cytarabine in Relapse/Refractory Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Blood2014-12-063 citations